In 2021, a phase 1/2 trial evaluated a therapeutic vaccine (IO102/IO103) and PD-L1 in combination with nivolumab; the combination showed favorable antitumor activity among metastatic melanoma patients (72). This evidence concerns the gene CD274 and metastatic melanoma.